- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Lilly names new head of cancer drug business
February 11, 2011
Associated PressEli Lilly and Co. on Friday named company insider Sue Mahony as president of its cancer drug business.
MoreRecent successes don't change Lilly's outlook
February 9, 2011
J.K. WallEli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past
18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have
paltry sales prospects.
MoreLilly collaboration with outside researchers yields first deal
February 8, 2011
Chris O'MalleyEli Lilly and Co.'s PD2 project attracted 30,000 compounds from researchers in 26 countries. And Lilly scientist Alan Palkowitz
said it's just the first of many such collaborations.
MoreTechnicality delays council's North of South vote
February 8, 2011
Tom HartonA technicality caused the City-County Council on Monday night to put off a final vote on the massive North of South mixed-use
project slated to be built on 14 acres north of the Eli Lilly and Co. corporate campus.
MoreStruggling Lilly turns to antidepressant Cymbalta for lift
February 5, 2011
Greg AndrewsCymbalta racked up $3.5 billion in sales last year, and some analysts say it may approach $5 billion before generic competition
arrives in 2013.
More2010 compensation fell about 20 percent for top Lilly execs
February 4, 2011
J.K. WallCompensation for Eli Lilly and Co.’s top executives fell last year due to a change to its stock award program and as
the company struggled to bring new medicines to market.
MoreLilly, Bristol-Myers halt enrollment in lung-cancer trial
February 2, 2011
J.K. WallEli Lilly and Co. and Bristol-Myers Squibb Co. stopped enrolling new patients in a clinical trial of an experimental lung
cancer drug over concerns about patients developing blood clots.
MorePotential competitor to Lilly drug shows promise in study
February 2, 2011
IBJ Staff and Bloomberg NewsSanofi-Aventis's experimental diabetes drug lixisenatide, given to volunteer patients once a day, was at least as effective
as Eli Lilly and Co. and Amylin Pharmaceuticals Inc.'s twice-daily medicine Byetta, a study found.
MoreLilly's fourth-quarter profit surges, topping analysts' predictions
January 27, 2011
J.K. WallThe Indianapolis-based drugmaker earned $1.2 billion in the quarter, compared with $915 million in the same period a year
ago. Profit per share beat Wall Street forecasts by a penny.
MoreLilly product gets boost; Wall Street yawns
January 26, 2011
J.K. WallEli Lilly and Co. probably will get approval for its newly acquired imaging agent used to diagnose Alzheimer’s disease,
but so far analysts are unimpressed.
MoreHead of Lilly's oncology unit resigning
January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
MoreVanderbilt rejected by high court on Cialis patents
January 24, 2011
Bloomberg NewsSupreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against
Eli Lilly's Icos subsidiary.
MoreIndiana companies prepping for burst of acquisitions
January 22, 2011
Francesca JaroszConditions are ripe for a barrage of mergers and acquisitions to take place this year.
MoreLilly imaging drug fails to win FDA panel's backing
January 21, 2011
Bloomberg NewsEli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA
advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results
of brain scans are read consistently, they said.
MoreDeCoudreaux leaving Lilly for top job at Mills College
January 20, 2011
J.K. WallAlecia DeCoudreaux, the top attorney for Eli Lilly and Co.’s U.S. unit and an active community volunteer, will leave
to become president of Mills College in California on July 1.
MoreDown on luck, Lilly finds comfort in pets
January 19, 2011
J.K. WallEli Lilly and Co. continues to misfire on getting new human medicines approved, but its animal health unit is on a roll.
MoreCarmel firm gets FDA approval for lice treatment
January 18, 2011
IBJ StaffParaPRO LLC's treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
MoreLilly imaging drug isn't ready for approval, FDA says
January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval,
according to U.S. regulators.
MorePanel says Lilly’s Solpura isn’t ready for approval
January 12, 2011
Bloomberg NewsEli Lilly and Co. failed to win an FDA advisory panel’s recommendation to introduce the first pancreatic enzyme that
isn’t derived from pig parts.
MoreDeal could give Lilly full diabetes deck
January 12, 2011
J.K. WallEli Lilly and Co.'s diabetes partnership with Boehringer Ingelheim GmbH represents a new kind of disease-focused strategy
that some consultants think is key to pharma companies’ futures.
MoreUPDATE: Analysts praise Lilly diabetes deal with Boehringer
January 11, 2011
J.K. WallThe deal Eli Lilly and Co. announced Tuesday morning with Boehringer Ingelheim GmbH sounded a lot like a baseball trade—with
five drugs and payments to be named later—but analysts and investors generally liked what they heard.
MoreLilly agrees to pay up to $1.2B for diabetes drugs
January 11, 2011
J.K. WallA complex deal with Boehringer Ingelheim also gives the German company rights to two experimental Lilly insulins.
MoreLilly's Solpura may lack data to prove effectiveness
January 10, 2011
Bloomberg NewsOutside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency
caused by cystic fibrosis, chronic pancreatitis or other conditions.
MoreLilly bumped up federal lobbying in third quarter
January 4, 2011
Associated PressThe Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the
same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.
MoreLilly, other big drugmakers shut out by FDA in 2010
January 3, 2011
IBJ Staff and Bloomberg NewsRegulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer
Inc., the world's largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same
time, according to agency records.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
So the Mayor adds another non value added layer to having a vehicle towed? Whereby the City Government RECIEVES AN ILLEGAL KICKBACK FROM A LGOISTICS COMPANY THAT SUBS THE WORK TO LOCAL TOW COMPANIES? What is the service the City performs for receiving the "tribute"? This is RICO!!!!! What a corrupt and unnecessary layer. What a dirtbag Mayor and his cronies.
Owner occupied housing. Clear enough?
So people think I am paranoid. It's from experience in dealing with puds requested by developers who make major donations themselves to representatives, have nice fund raisers for those running for office and hide through pac's. then there are the public relation firms. You will note some pr comments below. You there Clyde Lee? My opinion. Commercial along 421, great. Multifamily housing, terrible idea that will change the town. Senior condos or zero lot line homes west, great. I suggest keeping all entries to commercial areas at 421. All entries to owner occupied on sycamore. Will keep the traffic on sycamore down some. Two other things. You can't trust what will be there in 10 years. Steve builds quality stuff, but areas change over time. Look at the changes at the wall mart center at 86th and 421 over the last 10 years. Look at the apartments and neighborhoods behind St Vincent's. Raintree properties WILL decrease in value if commercial and multifamily goes in near. It has already been happening around the bridges area. The houses that have been sold recently are way below market. Several deals not closed due to the Illinois construction and the whole unsurety of the bridges. It's pretty simple, Zionsville will approve the whole thing because the city council has been groomed over a LONG period of time for this. I might even suggest some are in their position as a result of this.
Esta, do you have a dog in this fight? You seem to really want to knock anyone against this project. No, I didn't move to Indiana for the architecture. I moved here for that red barn in the field. The horses and fields of corn. A place that is NOT overdeveloped. There are plenty of nearby places in Indianapolis that could be REDEVELOPED instead.
RKW - OK, we get it, you're paranoid. The question is, are you paranoid enough? Greg - Yes, Pittman(s) is (are) at it again. They are developers, they build things. It's what they do. So when you go to work tomorrow, Greg, you're at it again too. Cliff - Really? You moved to Indiana for its progressive architecture? That's like moving to England for the cuisine. Zionsvillain - The house you moved to was once a field or woods. I'm willing to bet folks were upset when that ground was plowed under and a house was built. But I guess now that you are in, everything should stop? "My house was OK, but the next one is sprawl." SE Guy - Please don't paint us with such a wide brush. Most reasonable Zionsville residents welcome planned, measured development.